ET 008
Latest Information Update: 24 Apr 2007
At a glance
- Originator Endocrine Technology LLC
 - Class
 - Mechanism of Action CD4 antigen inhibitors; Complement factor D inhibitors; Complement factor H inhibitors; Immunomodulators
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Anthrax
 
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
 - 22 Feb 2002 Preclinical development for Anthrax in USA (Unknown route)